Herein, we analyzed the role of the novel inhibitory checkpoint BTLA and its ligand, HVEM, in the regulation of leukemic and natural killer (NK) cells in CLL. This evidence concerns the gene BTLA and B-cell chronic lymphocytic leukemia.